Publication:
Does the use of gonadotropin-releasing hormone antagonists in natural IVF cycles for poor responder patients cause more harm than benefit

dc.contributor.coauthorAksoy, Senai
dc.contributor.coauthorSeyhan, Ayse
dc.contributor.coauthorAlatas, Cengiz
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorAta, Mustafa Barış
dc.contributor.kuauthorÖktem, Özgür
dc.contributor.kuauthorUrman, Cumhur Bülent
dc.contributor.kuauthorYakın, Kayhan
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T23:03:05Z
dc.date.issued2016
dc.description.abstractPoor ovarian response to controlled ovarian stimulation (COS) is one of the most critical factors that substantially limits the success of assisted reproduction techniques (ARTs). Natural and modified natural cycle IVF are two options that could be considered as a last resort. Blocking gonadotropin-releasing hormone (GnRH) actions in the endometrium via GnRH receptor antagonism may have a negative impact on endometrial receptivity. We analysed IVF outcomes in 142 natural (n=30) or modified natural (n=112) IVF cycles performed in 82 women retrospectively. A significantly lower proportion of natural cycles reached follicular aspiration compared to modified natural cycles (56.7% vs. 85.7%, p<0.001). However, the difference between the numbers of IVF cycles ending in embryo transfer (26.7% vs. 44.6%) was not statistically significant between natural cycle and modified natural IVF cycles. Clinical pregnancy (6.7% vs. 7.1%) and live birth rates per initiated cycle (6.7% vs. 5.4%) were similar between the two groups. Notably, the implantation rate was slightly lower in modified natural cycles (16% vs. 25%, p>0.05). There was a trend towards higher clinical pregnancy (25% vs. 16%) and live birth (25% vs. 12%) rates per embryo transfer in natural cycles compared to modified natural cycles, but the differences did not reach statistical significance.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue2
dc.description.openaccessNO
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume19
dc.identifier.doi10.3109/14647273.2016.1158873
dc.identifier.eissn1742-8149
dc.identifier.issn1464-7273
dc.identifier.scopus2-s2.0-84961197871
dc.identifier.urihttps://doi.org/10.3109/14647273.2016.1158873
dc.identifier.urihttps://hdl.handle.net/20.500.14288/8406
dc.identifier.wos381304500005
dc.keywordsGnRH antagonist
dc.keywordsIVF
dc.keywordsNatural cycle
dc.keywordsPoor responder
dc.language.isoeng
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofHuman Fertility
dc.subjectObstetrics
dc.subjectGynecology
dc.subjectReproduction
dc.subjectBiology
dc.titleDoes the use of gonadotropin-releasing hormone antagonists in natural IVF cycles for poor responder patients cause more harm than benefit
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorYakın, Kayhan
local.contributor.kuauthorÖktem, Özgür
local.contributor.kuauthorAta, Mustafa Barış
local.contributor.kuauthorUrman, Cumhur Bülent
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files